Antibody-drug conjugates (ADCs) are antibody-based therapies that deliver cytotoxic agents to tumor cells. ADCs use monoclonal antibodies to deliver highly potent anti-cancer drugs to tumor cells, thereby allowing targeted delivery of the drug payload. The ability of ADCs to target and kill cancer cells while minimizing toxicity to healthy cells makes them an attractive option for cancer treatment. ADCs bind to antigen expressing cancer cells and are internalized followed by release of the cytotoxic drug intracellularly to induce cancer cell death. Currently, there are a handful of ADCs approved for the treatment of various cancers like breast cancer, lymphoma and leukemia.

The global Antibody Drug Conjugates Market is estimated to be valued at US$ 5.38 Bn in 2023 and is expected to exhibit a CAGR of 14.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/antibody-drug-conjugates-market-181

Market key trends:

One of the main trends in the antibody drug conjugates market is the shift towards newer generations of ADCs. Traditionally first generation ADCs had nonspecific conjugation of highly potent drugs to antibodies resulting in toxicity issues. However, newer generations of ADCs have overcome many of the previous challenges of early ADCs. Specifically, second and third generation ADCs have more stable linker technology allowing safer delivery of drug payloads with less toxicity. Additionally, third generation ADCs are utilizing multiple cytotoxic agents and even coupling with other treatment modalities like immune checkpoint inhibitors to enhance efficacy. The advancements in linker chemistry and payload engineering are helping realize the true potential of ADCs as targeted cancer therapies.

Porter’s Analysis

Threat of new entrants: Low, significant investments and resources required to enter into commercial manufacturing.
Bargaining power of buyers: Moderate, large pharmaceutical companies can negotiate prices.
Bargaining power of suppliers: Low, IP rights protect technology.
Threat of new substitutes: Low, complex technology and clinical trials required for new targeted therapies.
Competitive rivalry: High, major players compete in clinical development and marketing of ADC pipeline.

Key Takeaways

The global Antibody Drug Conjugates market is expected to witness high growth. The global alcoholic beverages market is estimated to be valued at US$ 1,769.41 Bn in 2023 and is expected to exhibit a CAGR of 2.5% over the forecast period 2023 to 2030.\

Regional analysis: North America is expected to dominate the ADC market during the forecast period, owing to presence of major players and higher adoption. Asia Pacific is poised to witness fastest growth during the forecast period attributed to increasing healthcare spending in countries such as China and India.

Key players: AstraZeneca PLC and Daiichi Sankyo Co are the major players in the Antibody Drug Conjugates market. AstraZeneca PLC has a robust late stage ADC pipeline while Daiichi Sankyo Co is marketing Enhertu for breast cancer.